Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
366 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (14)

Medical Condition

  • Show all (1928)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (38)
  • Bone & Muscle (10)
  • Cancer (748)
  • Child Development (4)
  • COVID-19 (Coronavirus) (37)
  • Critical Illness (1)
  • Dental (2)
  • Developmental Disorders (2)
  • Diabetes (22)
  • Ear, Nose and Throat (11)
  • Endocrine & Metabolic Disease (13)
  • (-) Eye (8)
    • Glaucoma (3)
  • Gastrointestinal and Digestive Diseases (22)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (175)
  • Heart Disease (129)
  • Infectious Disease (48)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (49)
  • Lung Disease (32)
  • Meniere's Disease (1)
  • Neurological Disorders (176)
  • Nutrition (4)
  • Obesity (10)
  • Obstetrics & Gynecology (52)
  • Pain Management (1)
  • Pediatrics (104)
  • Psychiatric Disorders (65)
    • ADD/ADHD (2)
    • Anxiety (4)
    • (-) Bipolar Disorder (6)
    • Borderline Personality Disorder (1)
    • Depression (23)
    • Eating Disorders (2)
    • Obsessive Compulsive Disorder (OCD) (10)
    • PTSD (3)
    • Schizophrenia (6)
  • Rehabilitation (8)
  • Stroke (7)
  • Surgery (7)
  • Transplant (51)
  • Urology (4)
  • Vascular Conditions (9)
Displaying 1 - 14 of 14

Topotecan in treatment of retinoblastoma

Condition: Eye
Investigator: Brian Marr, MD
Status: Closed
In this research study we want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with…
Read More

HORIZON: Gene Therapy for Dry Age-Related Macular Degeneration

Condition: Eye
Investigator: Tongalp Tezel, MD
Status: Closed
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in individuals with geographic atrophy secondary to dry age-related macular degeneration (AMD) who qualify, based on genetic testing.
Read More

Brain imaging in bipolar depression to understand the role of inflammation in its treatment.

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Martin Lan, MD
Status: Closed
This is a research study to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of inflammation in the process. If you participate, you will receive an experimental medication for your depression named ethyl eicosapentaenoic acid (ethyl EPA), an omega 3 fatty acid. You will…
Read More

Research Study offering Treatment for Self-Injury (Bipolar Disorder)

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Jeffrey Miller, MD
Status: Closed
The goal of this study is to examine how effective and well-tolerated a possible new treatment for individuals who injure themselves frequently will be. All research procedures can be done from home no in-person visits are required. We are studying a minimal-risk form of electrical brain stimulation called transcranial direct current stimulation, or tDCS.…
Read More

Research Study of New Treatment Called NT-501 (Encapsulated Cell Therapy (ECT) Implant) for Glaucoma

Condition: Eye / Glaucoma
Investigator: George Cioffi, MD
Status: Closed
Glaucoma is a given name of a group of diseases that affect the retinal ganglion cells in the eye and the optic nerve. Glaucoma cause degeneration of the retinal ganglion cells in the retina and their projections (axons) that form the optic nerve. Retinal ganglion cells and their axons transmit all of our vision information from the eye to the brain through…
Read More

Study for Subjects with Age-Related Macular Degeneration using investigational drug Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily.

Condition: Eye
Investigator: Tongalp Tezel, MD
Status: Closed
Macular degeneration is a progressive eye disease that damages the macula. The macula is the part of the eye that is responsible for central vision, which is needed to perform straight-ahead activities, such as reading, driving, or watching TV. This research is being conducted to learn about the safety and efficacy (how effectively the study drug works) of…
Read More

Brain imaging in bipolar depression to understand the antidepressant mechanism of lurasidone (Latuda).

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Martin Lan, MD
Status: Closed
We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. Particularly, we are looking at the importance of dopamine signaling in the process. If you participate, you will have two different brain scans (MRI and PET scan). You will also have treatment for your depression with an FDA approved medication,…
Read More

A study for patients with Glaucoma or Ocular Hypertension using study drug Bimatoprost SR

Condition: Eye / Glaucoma
Investigator: Lama Al-Aswad, MD, MPH
Status: Closed
This study is for patients with Glaucoma. The purpose of this study is to investigate the safety and effectiveness of a study drug called Bimatoprost Sustained Release (SR) compared to treatment with eye drug Timolol. The Bimatoprost SR is an implant that is very small, is biodegradable (dissolves naturally in the body), and contains the bimatoprost drug.
Read More

Lumateperone for the Treatment of Bipolar Disorder

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: David Hellerstein, MD
Status: Closed
This study is a double-blind and placebo-controlled study to assess its efficacy of the new drug Lumateperone for patients with Major Depressive Episodes associated with Bipolar I and Bipolar II disorder. Lumateperone is thought to exert its antidepressant effect through interaction with sereotogenic, dopaminergic, and glutamergic neurotransmitter targets.…
Read More

A study for patients with Stargardt disease using study drug ALK-001

Condition: Eye
Investigator: Stephen Tsang, MD, PhD
Status: Closed
Stargardt macular degeneration isa genetic condition, which in mostcases causes vision loss early in lifeand leads to legal blindness. Thereis currently no FDA-approvedtreatment.This trial will evaluate the safetyand effects of ALK-001, a newpotential drug treatment, on theprogression of Stargardt disease.ALK-001 is a capsule administereddaily by mouth.This…
Read More

MRI Effects of D-cycloserine & Lurasidone in Bipolar Depression

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Joshua Kantrowitz, Md
Status: Closed
We will evaluate the D-cycloserine (DCS) and lurasidone with MRI measurement of brain responses to DCS. DCS is a drug that works on the same brain receptor as ketamine. DCS is not approved by the FDA for bipolar depression. Study participants will receive a dose of lurasidone or placebo in one MRI and a dose of DCS in another, followed by an optional follow…
Read More

Nutritional Supplements and Visual Field Testing (ages 40-80)

Condition: Eye / Glaucoma
Investigator: Jeffrey Liebmann, MD
Status: Closed
Glaucoma is the leading cause of irreversible blindness worldwide. The most important test to detect progression is visual field testing. However, this test is very subjective, often unreliable, and variable. One of the main causes of unreliable tests is the lack of attentiveness or concentration during the test. Previous studies have shown that listening…
Read More

Study for Subjects with Age-Related Macular Degeneration using investigational drug Abicipar Pegol (AGN-150998)

Condition: Eye
Investigator: Tongalp Tezel, MD
Status: Closed
The abicipar is an injectable medication stored as a liquid in a single-use glass vial for delivery into the back of the eye. The active component is a protein drug that was made using bioengineering technology. It was designed to bind to and inactivate a protein called Vascular Endothelial GrowthFactor (VEGF) that plays an important role in causing AMD.…
Read More

Brain imaging in bipolar depression to be able to predict who will respond to antidepressant treatment

Condition: Psychiatric Disorders / Bipolar Disorder
Investigator: Martin Lan, MD
Status: Closed
We are trying to understand what causes bipolar disorder and how medications treat bipolar depression. If you participate, you will have two different brain scans (MRI and PET scan). You will also have antidepressant treatment for free. We will then be able to see whether information on the brain scans connects with how people do on the medications. The…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science